Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models

Launched by XINHUA HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Feb 6, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on improving the diagnosis of certain childhood cancers, specifically five types of solid tumors: neuroblastoma, medulloblastoma, Wilms tumor, hepatoblastoma, and rhabdomyosarcoma. Researchers aim to create a new system that uses advanced technology to help doctors better identify and classify these tumors. Currently, diagnosing these cancers can be complicated, and this study seeks to gather high-quality images and diagnostic information to make the process more accurate and efficient. By doing so, the trial hopes to support personalized treatment plans for young patients.

To be eligible for this study, participants must be between the ages of 0 and 18 and have a confirmed diagnosis of one of the targeted tumors based on specific medical criteria. This means, for example, that a child with neuroblastoma must have had a diagnosis confirmed through tissue samples or specific tests. If a child qualifies and chooses to participate, they can expect to contribute to research that may lead to better diagnostic tools and treatment for pediatric cancers in the future. It's important to note that this study is not yet recruiting participants, so there will be more information available as it progresses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Neuroblastoma (NB): For newly diagnosed patients with NB aged 0-18 years, the diagnosis criteria are one of the following two items: (1) the patient's tumor tissue has obtained a positive pathological diagnosis under the light microscope; (2) Bone marrow biopsy or aspiration revealed characteristic neuroblastoma cells, which were small round cells, arranged in a nested or chrysanthemum clump or positive staining for anti-GD2 antibodies, and accompanied by an increase in urinary vanillylmandelic acid (VMA) and an increase in blood neuron-specific enolase (NSE).
• • 2. Wilms tumor (nephroblastoma): patients aged 0-18 years old who have been diagnosed with Wilms tumor by histopathology.
• • 3. Hepatoblastoma (HB): Patients aged 0-18 years who have been diagnosed with hepatoblastoma by histopathology.
• • 4. Medulloblastoma (MB): Patients aged 0-18 years with a confirmed histopathological diagnosis of medulloblastoma.
• • 5. rhabdomyosarcoma (RMS): patients aged 0-18 years old who have been diagnosed with medulloblastoma by histopathology.
• Exclusion Criteria:
• • 1. The patient's medical record and treatment follow-up information are incomplete; HE is not stained or faded
• • 2. Those who have 2 or more types of tumors at the same time;
• • 3. Those who do not meet the enrollment criteria.
• • 4. Tumor subtype with less than 3 WSI images